KALA

0001479419false00014794192025-08-082025-08-08 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025

KALA BIO, Inc. (Exact Name of Registrant as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On August 8, 2025, KALA BIO, Inc. announced its financial results for the quarter ended June 30, 2025 and provided a general business and corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated August 8, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: August 8, 2025 By: /s/ Mary Reumuth

Mary Reumuth

Chief Financial Officer and Corporate Secretary

​ ​ ​ ​

0001479419false00014794192025-05-142025-05-14 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025

KALA BIO, Inc. (Exact Name of Registrant as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On May 14, 2025, KALA BIO, Inc. announced its financial results for the quarter ended March 31, 2025 and provided a general business and corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated May 14, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: May 14, 2025 By: /s/ Mary Reumuth

Mary Reumuth

Chief Financial Officer and Corporate Secretary

​ ​ ​ ​

0001479419false00014794192025-03-312025-03-31 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025

KALA BIO, Inc. (Exact Name of Registrant as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On March 31, 2025, KALA BIO, Inc. announced its financial results for the quarter and year ended December 31, 2024 and provided a general business and corporate update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated March 31, 2025

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: March 31, 2025 By: /s/ Mary Reumuth

Mary Reumuth

Chief Financial Officer and Corporate Secretary

​ ​ ​ ​

NASDAQ0001479419false00014794192024-11-122024-11-12 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024

KALA BIO, Inc. (Exact Name of Registrant as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On November 12, 2024, KALA BIO, Inc. announced its financial results for the quarter ended September 30, 2024 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated November 12, 2024

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: November 12, 2024 By: /s/ Mary Reumuth

Mary Reumuth

Chief Financial Officer and Corporate Secretary

​ ​ ​ ​

NASDAQ0001479419false00014794192024-08-062024-08-06 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2024

KALA BIO, Inc. (Exact Name of Registrant as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On August 6, 2024, KALA BIO, Inc. announced its financial results for the quarter ended June 30, 2024 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated August 6, 2024

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: August 6, 2024 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer and Corporate Secretary

​ ​ ​ ​

NASDAQ0001479419false00014794192024-05-142024-05-14 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024

KALA BIO, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On May 14, 2024, KALA BIO, Inc. announced its financial results for the quarter ended March 31, 2024 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated May 14, 2024

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: May 14, 2024 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

NASDAQ0001479419false00014794192024-03-292024-03-29 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2024

KALA BIO, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On March 29, 2024, KALA BIO, Inc. announced its financial results for the quarter and year ended December 31, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated March 29, 2024

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: March 29, 2024 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

NASDAQ0001479419false00014794192023-11-132023-11-13 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023

KALA BIO, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On November 13, 2023, KALA BIO, Inc. announced its financial results for the quarter ended September 30, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated November 13, 2023

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: November 13, 2023 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

NASDAQ0001479419false00014794192023-08-042023-08-04 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2023

KALA BIO, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Kala Pharmaceuticals, Inc. (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02.   Results of Operations and Financial Condition. On August 4, 2023, KALA BIO, Inc. announced its financial results for the quarter ended June 30, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of KALA BIO, Inc. dated August 4, 2023

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA BIO, INC.

Date: August 4, 2023 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

NASDAQ0001479419false00014794192023-05-092023-05-09 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02   Results of Operations and Financial Condition. On May 9, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of Kala Pharmaceuticals, Inc. dated May 9, 2023

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA PHARMACEUTICALS, INC.

Date: May 9, 2023 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

NASDAQ0001479419false00014794192023-03-032023-03-03 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Not applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​

Item 2.02   Results of Operations and Financial Condition. On March 3, 2023, Kala Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2022 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of Kala Pharmaceuticals, Inc. dated March 3, 2023

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA PHARMACEUTICALS, INC.

Date: March 3, 2023 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

0001479419false00014794192022-11-082022-11-08 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ​ ​ ​ ​

Item 2.02   Results of Operations and Financial Condition. On November 8, 2022, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of Kala Pharmaceuticals, Inc. dated November 8, 2022

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA PHARMACEUTICALS, INC.

Date: November 8, 2022 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

0001479419false00014794192022-08-112022-08-11 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2022

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ​ ​ ​ ​

Item 2.02   Results of Operations and Financial Condition. On August 11, 2022, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2022 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of Kala Pharmaceuticals, Inc. dated August 11, 2022

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA PHARMACEUTICALS, INC.

Date: August 11, 2022 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

0001479419false00014794192022-05-162022-05-16 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2022

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ​ ​ ​ ​

Item 2.02   Results of Operations and Financial Condition. On May 16, 2022, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2022 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of Kala Pharmaceuticals, Inc. dated May 16, 2022

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA PHARMACEUTICALS, INC.

Date: May 16, 2022 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

0001479419false00014794192022-03-292022-03-29 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2022

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 1167 Massachusetts Avenue Arlington, MA 02476 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ​ ​ ​ ​

Item 2.02   Results of Operations and Financial Condition. On March 29, 2022, Kala Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2021 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. ​ Item 9.01.  Financial Statements and Exhibits. (d)     Exhibits. ​

​

​

​

99.1 Press Release of Kala Pharmaceuticals, Inc. dated March 29, 2022

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA PHARMACEUTICALS, INC.

Date: March 29, 2022 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

0001479419false00014794192021-11-122021-11-12 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 490 Arsenal Way, Suite 120 Watertown, MA 02472 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ​ ​ ​ ​

​ Item 1.01. Entry into a Material Definitive Agreement. ​ On November 15, 2021, Kala Pharmaceuticals, Inc. (the “Company”) and its newly formed, direct wholly owned subsidiary, Ceres Merger Sub, Inc. (the “Merger Subsidiary”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Combangio, Inc. (“Combangio”) and Fortis Advisors LLC, solely in its capacity as Combangio Equityholder Representative in connection with the Merger Agreement, pursuant to which on November 15, 2021, the Merger Subsidiary merged with and into Combangio with Combangio surviving such merger and becoming a direct wholly owned subsidiary of the Company (the “Acquisition”). Combangio is a clinical-stage biotechnology company focused on developing regenerative biotherapeutics for severe ocular diseases based on mesenchymal stem cell (“MSCs”) secretomes, including, its lead product candidate, CMB-012 for the treatment of persistent corneal epithelial defects (“PCED”). Following the Acquisition, the Company refers to CMB-012 as KPI-012. ​ In connection with the closing of the Acquisition on November 15, 2021 (the “Closing”), the Company made an upfront payment of an aggregate of $5.0 million in cash to former Combangio stockholders and other equityholders (the “Combangio Equityholders”), subject to customary adjustments, and agreed to issue an aggregate of 7,788,667 shares (the “Post-Closing Stock Consideration”) of the Company’s common stock, $0.001 par value per share (the “Common Stock”), to the Combangio Equityholders with an aggregate value of approximately $16,122,541, consisting of (i) an aggregate of 6,815,129 shares of Common Stock to be issued on January 3, 2022 and (ii) an aggregate of 973,538 shares of Common Stock that will be held back by the Company and will be issuable subject to the terms of the Merger Agreement to the Combangio Equityholders on the Escrow Release Date (as defined below) (the “Initial Holdback Shares”). The aggregate value of the Post-Closing Stock Consideration was calculated using the closing price of the Company’s Common Stock on the Nasdaq Global Select Market on November 12, 2021, the last trading day prior to the Closing. The Post-Closing Stock Consideration constitutes approximately 11.9% of the Company’s Common Stock outstanding as of immediately prior to the Closing. ​ In addition, pursuant to the Merger Agreement, the Combangio Equityholders, in the aggregate and subject to the terms and conditions of the Merger Agreement, will also be entitled to receive from the Company the following contingent consideration (the “Contingent Consideration”): ​ ●up to $105.0 million in contingent milestone consideration, of which (i) $2.3 million would become payable in cash and $2.7 million would be payable in shares of the Company’s Common Stock upon the first patient dosed with any product candidate whose active ingredient comprises one or more biological factors secreted by MS

0001479419false00014794192021-08-052021-08-05 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 490 Arsenal Way, Suite 120 Watertown, MA 02472 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ​ ​ ​ ​

​ Item 2.02   Results of Operations and Financial Condition. On August 5, 2021, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended June 30, 2021 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01  Financial Statements and Exhibits. (d)     Exhibits: ​ ​

​

99.1 Press Release of Kala Pharmaceuticals, Inc. dated August 5, 2021

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA PHARMACEUTICALS, INC.

Date: August 5, 2021 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

0001479419false00014794192021-05-052021-05-05 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 490 Arsenal Way, Suite 120 Watertown, MA 02472 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ​ ​ ​ ​

​ Item 2.02   Results of Operations and Financial Condition. On May 5, 2021, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended March 31, 2021 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01  Financial Statements and Exhibits. (d)     Exhibits: ​ ​

​

99.1 Press Release of Kala Pharmaceuticals, Inc. dated May 5, 2021

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA PHARMACEUTICALS, INC.

Date: May 5, 2021 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

0001479419false00014794192021-02-252021-02-25 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2021

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 490 Arsenal Way, Suite 120 Watertown, MA 02472 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ​

​

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ​ ​ ​ ​

​ Item 2.02   Results of Operations and Financial Condition. On February 25, 2021, Kala Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2020 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 9.01  Financial Statements and Exhibits. (d)     Exhibits: ​ ​

​

99.1 Press Release of Kala Pharmaceuticals, Inc. dated February 25, 2021

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

​ ​ ​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ​ ​

​

​

KALA PHARMACEUTICALS, INC.

Date: February 25, 2021 By: /s/ Mary Reumuth

Name: Mary Reumuth

Title: Chief Financial Officer

​ ​ ​ ​

0001479419false00014794192021-01-072021-01-07 ​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2021

Kala Pharmaceuticals, Inc. (Exact Name of Company as Specified in its Charter)

​ ​

​

​

Delaware 001-38150 27-0604595

(State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

​ 490 Arsenal Way, Suite 120 Watertown, MA 02472 (Address of Principal Executive Offices) (Zip Code) Company’s telephone number, including area code: (781) 996-5252 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ​ ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

​ ​

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

​ ​

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

​ ​

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

​ Securities registered pursuant to Section 12(b) of the Act: ​ ​

​

​

Title of each class Trading symbol(s) Name of each exchange on which registered

Common Stock, $0.001 par value per share

KALA

The Nasdaq Global Select Market

​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒ ​ ​ ​

Item 2.02.      Results of Operations and Financial Condition. On January 7, 2021, Kala Pharmaceuticals, Inc. (the “Company”) issued a press release to announce the commercial launch of EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, its product for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Although the Company has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2020, the Company disclosed in the press release that it expects to report cash, cash equivalents and short-term investments of approximately $153.5 million as of December 31, 2020. The estimated cash, cash equivalents and short-term investments figure includes net proceeds generated from the sale of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) under its “at-the-market” offering program during the fourth quarter of 2020. The press release is attached hereto as Exhibit 99.1. The estimated cash, cash equivalents and short-term investments figure is preliminary and unaudited, represents management’s estimate as of the date of this report and is subject to completion of the Company’s financial closing procedures. The Company’s independent registered public accounting firm has not conducted an audit or review of, and does not express an opinion or any other form of assurance with respect to, the estimated cash, cash equivalents and short-term investments figure. The information in this Item 2.02 is furnished under Item 2.02 of Form 8-K, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such a filing. Item 8.01.      Other Events. Commercial Launch of EYSUVIS On January 7, 2021, the Company issued a press release to announce the commercial launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, its product for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. The information set forth in Item 2.02 of this Form 8-K regarding the Company’s estimated, preliminary cash, cash equivalents and short-term investments as of December 31, 2020 is incorporated by reference into this Item 8.01. At-the-Market Offering Program Update As previously reported, on May 7, 2020, the Company entered into an Amended and Restated Sales Agreement (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), as agent, pursuant to which the Company may offer and sell shares of its Common Stock for aggregate gross sale proceeds of up to $75.0 million from time to time through Jefferies under an “at-the-market” offering program.